Its mission[1] is to identify novel molecular targets and discover small molecules by utilizing its proprietary platforms to diagnose, treat and address serious unmet global public health needs.

Institut Pasteur Korea is also focused on discovery biology to study and understand TB and on the development of new and more effective ways to diagnose and treat the disease.

These functional units collaborate across disciplines and classical research boundaries, providing an effective operational organization to meet the strategic goals of the institute.

By screening with siRNA libraries, researchers can identify genes that alter drug sensitivity in the cellular disease model, thereby providing a way to quickly close in on the molecular targets.

Institut Pasteur Korea is funded through Korean government subsidies from the Ministry of Science and ICT, domestic and international grants, revenues from industry-sponsored research and license agreements, and donations.